Literature DB >> 22529202

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

S D Silberstein1, S Holland, F Freitag, D W Dodick, C Argoff, E Ashman.   

Abstract

OBJECTIVE: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?
METHODS: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. RESULTS AND RECOMMENDATIONS: The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22529202      PMCID: PMC3335452          DOI: 10.1212/WNL.0b013e3182535d20

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

2.  Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.

Authors:  M Siniatchkin; W D Gerber; A Vein
Journal:  Funct Neurol       Date:  1998 Jan-Mar

3.  Topiramate in migraine prevention: a double-blind, placebo-controlled study.

Authors:  J R Storey; C S Calder; D E Hart; D L Potter
Journal:  Headache       Date:  2001 Nov-Dec       Impact factor: 5.887

4.  Fluoxetine prophylaxis of migraine.

Authors:  C Adly; J Straumanis; A Chesson
Journal:  Headache       Date:  1992-02       Impact factor: 5.887

5.  Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control.

Authors:  Hans-Christoph Diener; Peer Tfelt-Hansen; Carl Dahlöf; Miguel J A Láinez; Giorgio Sandrini; Shuu-Jiun Wang; Walter Neto; Ujjwalla Vijapurkar; Aiden Doyle; David Jacobs
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

6.  A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.

Authors:  Stephen D Silberstein; Arthur H Elkind; Curtis Schreiber; Charlotte Keywood
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

7.  Topiramate in migraine prevention: results of a large controlled trial.

Authors:  Stephen D Silberstein; Walter Neto; Jennifer Schmitt; David Jacobs
Journal:  Arch Neurol       Date:  2004-04

8.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

9.  Double-blind trial of fluoxetine: chronic daily headache and migraine.

Authors:  J R Saper; S D Silberstein; A E Lake; M E Winters
Journal:  Headache       Date:  1994-10       Impact factor: 5.887

10.  Topiramate for migraine prevention: a randomized controlled trial.

Authors:  Jan Lewis Brandes; Joel R Saper; Merle Diamond; James R Couch; Donald W Lewis; Jennifer Schmitt; Walter Neto; Stefan Schwabe; David Jacobs
Journal:  JAMA       Date:  2004-02-25       Impact factor: 56.272

View more
  176 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

Review 2.  Symptoms of Concussion and Comorbid Disorders.

Authors:  Cherry Junn; Kathleen R Bell; Christian Shenouda; Jeanne M Hoffman
Journal:  Curr Pain Headache Rep       Date:  2015-09

Review 3.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

4.  Prophylaxis of migraine in children.

Authors:  Satinder Aneja
Journal:  Indian J Pediatr       Date:  2013-10-17       Impact factor: 1.967

Review 5.  Improving medication adherence in migraine treatment.

Authors:  Elizabeth K Seng; Jeanetta A Rains; Robert A Nicholson; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2015-06

Review 6.  Therapeutic antibodies against CGRP or its receptor.

Authors:  Marcelo E Bigal; Sarah Walter; Alan M Rapoport
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

7.  PURLs: Consider melatonin for migraine prevention.

Authors:  Corey Lyon; Shannon Langner
Journal:  J Fam Pract       Date:  2017-05       Impact factor: 0.493

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 9.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

10.  Vitamin D in migraine headache: a comprehensive review on literature.

Authors:  Zeinab Ghorbani; Mansoureh Togha; Pegah Rafiee; Zeynab Sadat Ahmadi; Reyhaneh Rasekh Magham; Samane Haghighi; Soodeh Razeghi Jahromi; Maryam Mahmoudi
Journal:  Neurol Sci       Date:  2019-08-03       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.